In any event, do see this -- from Lexology
. . . .On June 20, 2014, the Patent Trial and Appeal Board (PTAB) issued the first inter partesreview (IPR) decisions reaching pharmaceutically-related subject matter, which in this case constituted dietary supplement and vitamin products. Four separate final written decisions, addressing four respective patents claiming related subject matter, held claims unpatentable directed to pharmaceutical compositions and methods of treatment using such compositions. . . .
[Ruled non-patenetable were] compositions containing a natural isomer of a reduced folate (e.g., 5-methyl-(6S)-THF), as an alternative to folic acid, which some individuals reportedly do not absorb easily. Petitioner essentially relied upon one prior art reference disclosing preparations for the use of folate or an undefined suitable active metabolite, and another disclosing the natural folate metabolite 5-methyl-(6S)-THF for treating folate deficiency. Despite Patent Owners’ reliance on nearly a dozen experts and other declarants’ testimony rebutting the combination, the PTAB found all challenged claims either anticipated or rendered obvious by the prior art. . . .
Yes, this is (or will soon be) on appeal, but it means that Merck may not file patent infringement claims for dietary supplements using the 5-methyl isomer as a folate deficiency remedy. Immaterial (to Merck) but entertaining -- and good news for Gnosis. Now you. . . know. Be kind to one another. . . GO USA -- spank Belgium!
2 comments:
So, you have your own thread over on CP!
You must have pissed someone off.
Yes. Pretty silly actually.
But I'll not spend even a moment wondering who -- or why, about that.
Life is too wonderful, precious and short to worry about fuss-budgets!
Namaste!
Do stop back -- from time to time. But I never worked for Fred... At all.
Post a Comment